LABORATORIOS LESVI, S.L.
|LABORATORIOS LESVI, S.L. Patent applications|
|Patent application number||Title||Published|
|20140142158||STABLE MICRONISED MONOCLINIC FORM OF ASENAPINE MALEATE AND ITS SYNTHESIS - A stable micronised monoclinic form of asenapine maleate is described, which comprises 5% by weight or less of orthorhombic form or any other crystalline form of asenapine maleate, wherein the asenapine maleate has a particle size distribution characterised by a d90 equal to or below 40 μm. Processes for preparing the stable micronised monoclinic form of asenapine maleate are also described. Formula (I).||05-22-2014|
|20130289287||PROCESS FOR OBTAINING DRONEDARONE - The present invention provides a process for obtaining dronedarone or salts thereof characterized in that in an organic phase comprising one or more non-polar solvents, 5-amino-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-2-n-butyl-benzofuran is reacted with methane sulfonyl chloride without the addition of a base. The invention also provides a process for obtaining intermediates of dronedarone environmentally friendly and industrially viable.||10-31-2013|
|20130225835||NOVEL PROCESS FOR THE PREPARATION OF ASENAPINE - The present invention is directed to novel compounds of formula (I) as well as to the process for their preparation. Novel compounds of formula (I) can be converted into asenapine through an efficient process. The invention also relates to novel intermediates used in this process and their use in the preparation of compounds of formula (I).||08-29-2013|
|20130045998||PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE - The present invention refers to an improved method for the preparation of compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid substantially free of its 3H-I isomer. The invention also refers to the use of said intermediate for the preparation of Rufinamide and for obtaining a new polymorphic form of Rufinamide, designed as Form R-5. The invention also refers to said new polymorph of Rufinamide, and to the composition containing it and its use as medicament. The new polymorph of Rufinamide shows good stability and appropriate physico-chemical properties for its manipulation on industrial scale. Polymorph Form R-5 will be suitable to use as pharmaceutical for the treatment of convulsions, especially for the treatment of epilepsy.||02-21-2013|
|20110223211||PHARMACEUTICAL FORMULATIONS CONTAINING IRBESARTAN - The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally combined with a diuretic and to a process for the manufacture of said composition.||09-15-2011|
|20100297031||ORODISPERSIBLE TABLETS - This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.||11-25-2010|
|20090214646||PHARMACEUTICAL FORMULATIONS CONTAINING CLOPIDOGREL - The present invention relates to a composition comprising a pharmaceutically acceptable salt of Clopidogel and isomalt as a diluent, to the use of said composition in the elaboration of an oral pharmaceutical formulation, as well as to an oral pharmaceutical formulation comprising said composition.||08-27-2009|
|20090155369||PHARMACEUTICAL COMPOSITION CONTAINING LEVODOPA, ENTACAPONE AND CARBIDOPA - The present invention refers to a solid pharmaceutical composition of entacapone, levodopa and carbidopa or pharmaceutically acceptable salts thereof characterized in that entacapone is in the form of granules and it is added separately to levodopa and carbidopa. In addition, this invention provides the process for its preparation.||06-18-2009|
|20090136571||PHARMACEUTICAL FORMULATIONS CONTAINING IRBESARTAN - The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally combined with a diuretic and to a process for the manufacture of said composition.||05-28-2009|
Patent applications by LABORATORIOS LESVI, S.L.